Quick Answer
GILEAD SCIENCES, INC. reported Cash and Equivalents of $5.41 billion for fiscal year 2022.
GILEAD SCIENCES, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2022 | $5.41B | +1.4% |
| 2021 | $5.34B | -11.0% |
| 2020 | $6.00B | -48.4% |
| 2019 | $11.63B | -35.2% |
| 2018 | $17.94B | +136.4% |
| 2017 | $7.59B | -7.8% |
| 2016 | $8.23B | -36.0% |
| 2015 | $12.85B | +28.2% |
| 2014 | $10.03B | +374.5% |
| 2013 | $2.11B | +17.1% |
| 2012 | $1.80B | -81.7% |
| 2011 | $9.88B | +988.7% |
| 2010 | $907.88M | -28.7% |
| 2009 | $1.27B | -12.8% |
| 2008 | $1.46B | +50.7% |
| 2007 | $968.09M | +18.6% |
| 2006 | $816.01M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| June 30, 2019 | $11.24B | -15.1% | -33.6% |
| March 31, 2019 | $16.93B | +121.5% | -5.6% |
| December 31, 2018 | $17.94B | +136.4% | +23.1% |
| September 30, 2018 | $14.57B | +26.6% | +10.1% |
| June 30, 2018 | $13.23B | +51.9% | +73.2% |
| March 31, 2018 | $7.64B | -25.7% | +0.7% |
| December 31, 2017 | $7.59B | -7.8% | -34.1% |
| September 30, 2017 | $11.51B | +17.3% | +32.1% |
- GILEAD SCIENCES, INC. showed an increase of +1.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2006–2022 period, GILEAD SCIENCES, INC.’s cash and equivalents has grown by 563.2% (from $816.01 million to $5.41 billion).
- The most recent figure is from GILEAD SCIENCES, INC.’s fiscal year 2022 report (Form 10-K), filed with the SEC on February 22, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: